Nurix Therapeutics (NRIX) Retained Earnings: 2019-2025
Historic Retained Earnings for Nurix Therapeutics (NRIX) over the last 5 years, with Aug 2025 value amounting to -$925.0 million.
- Nurix Therapeutics' Retained Earnings fell 35.99% to -$925.0 million in Q3 2025 from the same period last year, while for Aug 2025 it was -$925.0 million, marking a year-over-year decrease of 35.99%. This contributed to the annual value of -$738.8 million for FY2024, which is 35.50% down from last year.
- Latest data reveals that Nurix Therapeutics reported Retained Earnings of -$925.0 million as of Q3 2025, which was down 10.30% from -$838.6 million recorded in Q2 2025.
- Over the past 5 years, Nurix Therapeutics' Retained Earnings peaked at -$128.0 million during Q1 2021, and registered a low of -$925.0 million during Q3 2025.
- Moreover, its 3-year median value for Retained Earnings was -$631.3 million (2024), whereas its average is -$650.2 million.
- Data for Nurix Therapeutics' Retained Earnings shows a maximum YoY plummeted of 118.66% (in 2021) over the last 5 years.
- Over the past 5 years, Nurix Therapeutics' Retained Earnings (Quarterly) stood at -$220.9 million in 2021, then plummeted by 81.65% to -$401.3 million in 2022, then plummeted by 35.87% to -$545.2 million in 2023, then plummeted by 35.50% to -$738.8 million in 2024, then tumbled by 35.99% to -$925.0 million in 2025.
- Its Retained Earnings was -$925.0 million in Q3 2025, compared to -$838.6 million in Q2 2025 and -$795.1 million in Q1 2025.